Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
runimotamab
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Runimotamab is a bispecific monoclonal antibody developed by Genentech (a subsidiary of F. Hoffmann-La Roche) for the treatment of HER2-expressing solid tumors, including metastatic breast cancer, gastric cancer, and adenocarcinoma of the gastroesophageal junction. It functions as a T-cell dependent bispecific antibody that simultaneously binds to CD3 on T cells and HER2 on tumor cells, crosslinking cytotoxic T lymphocytes with HER2-expressing cancer cells. This mechanism results in potent CTL-mediated lysis of tumor cells through antibody-dependent cell cytotoxicity and direct stimulation of T lymphocytes[1][2][3][5]. Runimotamab was administered intravenously in clinical trials but has been discontinued in Phase I development for its primary indications[2].
- Other names
- HER2xCD3 BiTEHER-2xCD3 BiTEHER 2xCD3 BiTE
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on runimotamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on runimotamab.